| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371324 | Bioorganic & Medicinal Chemistry Letters | 2015 | 5 Pages |
Abstract
Modulators of S1P1 have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P1 chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a ‘tricyclic fused indole array’ and are highly potent agonists of the S1P1 receptor.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Daniel J. Buzard, Thomas O. Schrader, Xiuwen Zhu, Juerg Lehmann, Ben Johnson, Michelle Kasem, Sun Hee Kim, Andrew Kawasaki, Luis Lopez, Jeanne Moody, Sangdon Han, Yinghong Gao, Jeff Edwards, Jeremy Barden, Jayant Thatte, Joel Gatlin, Robert M. Jones,